当前位置:
首页
网刊
关注中药新药临床研究中的心脏安全性
关注中药新药临床研究中的心脏安全性
朱贤慧1,刘炳林2,唐健元2,薛斐然2

1 南京中医药大学附属医院,南京 210029;2 国家食品药品监督管理总局药品审评中心,北京 100038
Spotlight on the cardiac safety of new traditional Chinese medicines in clinical trials
(1 The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029,China; 2 Centre for Drug Evaluation, China Food and Drug Administration, Beijing 100038, China)

摘要参考文献相关文章

起始页:1498

摘要:[摘要] 新药心脏安全性评价是新药临床研究中的重点之一,目前,中药新药临床研究中对心脏安全性的关注尚比较欠缺,存在设计欠规范、实施欠严谨、随访欠充分等问题,这与研究者的重视程度、中药新药的影响因素繁多、作用机制复杂等因素有关。在临床研究中,科学、合理、规范地评价中药新药的心脏安全性需要中西合璧、博古通今,注重临床研究两“期”(早期与长期),设计规范、合理、完善、具备可操作性的临床试验方案,客观、科学、均一地分析心脏安全性数据。

关键词:[关键词] 中药新药;临床研究;心脏安全性

通讯作者:

基金项目:

作者简介:

Abstract:[Abstract] Cardiac safety is one of the emphases which should be focused on in the clinical trials of new traditional Chinese medicines. However, there is little attention paid to this issue currently. Besides, there are some problems in the designing, processing and follow up of clinical trials because of the attitudes of the investigators, various influencing factors of new traditional Chinese medicines, and complicated mechanism and so on. It is important to evaluate the cardiac safety of new traditional Chinese medicines in a scientific, rational and standardized way by integrating the western and Chinese technology and learning from the ancient and modern theories. It is crucial to pay more attention to the early stage and long-term research of clinical trials. Besides, a standardized, rational, complete and practical protocol of clinical trial and an objective, scientific and consistent evaluation of cardiac safety data are very important.

Key words:[Key words] new traditional Chinese medicine; clinical trial; cardiac safety

    [1] VICENTE J, STOCKBRIDGE N, STRAUSS DG. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs[J].J Electrocardiol, 2016,49(6):837-842.
    [2] LEXCHIN J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004[J].CMAJ, 2005, 172(6):765-767.
    [3] TISDALE JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management[J]. Can Pharm J (Ott),2016, 149(3):139-152.
    [4] CURIGLIANO G, CARDINALE D, DENT S,et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management[J]. CA Cancer J Clin,2016,66(4):309-325.
    [5] CHEN A, ASHBURN MA. Cardiac effects of opioid therapy[J]. Pain Med,2015,16(Suppl 1): S27-S31.
    [6] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs[EB/OL]. (2016-10-06).http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073153.pdf.
    [7] ICH Topic S7B The nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals[EB/OL]. (2016-10-06).http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf. 
    [8] COLATSKY T, FERMINI B, GINTANT G, et al.The comprehensive in vitro proarrhythmia assay(CiPA) initiative-update on progress[J]. J Pharmacol Toxicol Methods, 2016,81:15-20.
    [9] 张庆辉. 附子理中丸中毒致心律失常1例[J]. 临床荟萃,2010,25(23):2082.
    [10] 陈龙.中药注射剂心脏安全性隐患及临床抢救对策[C].中国毒理学会第七次全国毒理学大会暨第八届湖北科技论坛论文集,2015.
    [11] 国家食品药品监督管理总局. 中药新药临床研究一般原则[EB/OL].2015. http://www.sda.gov.cn/WS01/CL1616/134582.html.
    [12] FERBER G, LORCH U, TUBEL J,et al. The power of phase I studies to detect clinical relevant QTc Prolongation: a resampling simulation study[J]. Biomed Res Int,2015, 2015:293564. doi: 10.1155/2015/293564.
    [13] HABEL LA, COOPER WO, SOX CM, et al. ADHD Medications and risk of serious cardiovascular disease in young and middle-aged adults[J]. JAMA,2011,306(24):2673-2683.
    [14] HOCH M, DARPO B, REMENOVA T, et al. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist[J]. Drug Des Dev Ther, 2014,17(9):175-185.
    [15] 李旻,李华,汪溪洁,等.蟾酥心脏毒性研究进展[J].中国药理学与毒理学杂志,2016,30(5):605-610.
    [16] BOFFITO M, JACKSON A, POZNIAK A, et al. Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-nave HIV-1-infected patients[J]. Drugs RD,2015,15(1):141-153.
    [17] SUGRUE A, KREMEN V, QIANG B, et al. Electrocardiographic predictors of torsadogenic risk during dofetilide or sotalol initiation: utility of a novel T wave analysis program[J]. Cardiovasc Drugs Ther,2015,29(5):433-441.
    [18] VICENTE J, JOHANNESEN L, MASON JW, et al. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil[J]. J Am Heart Assoc, 2015,4(4):1-13.
    [19] RABKIN SW. Impact of age and sex on QT prolongation in patients receiving psychotropics[J]. Can J Psychiatry,2015,60(5):206-214.
    [20] RABKIN SW, CHENG XB.Nomenclature, categorization and usage of formulae to adjust QT interval for heart rate[J]. World J Cardiol,2015,7(6): 315-325.